Home

Jeff Evanson

CIK 1760511 · CHIEF COMMERCIAL OFFICER · last filed 2024-03-22

Jeff Evanson is a CHIEF COMMERCIAL OFFICER who has filed 11 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing, for OTLK, was dated Mar 22, 2024. Across all open-market trades the lifetime net is −$589.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $53.4K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$53.4K

Companies

2

Total Filings

11

Lifetime Open-Market Net

-$589.8K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OTLK CHIEF COMMERCIAL OFFICER 40,423 $1.32 $53.4K -$473.9K 6 2024-03-22
Outlook Therapeutics, Inc. (OTLKW) Delisted Chief Commercial Officer 1,177,130 $0.03 $35.3K -$116.0K 5 2021-12-23

Recent Filings

11 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-03-22 OTLK Grant (A) — $0 EDGAR
2024-03-11 OTLK Buy (P) +62,484 $26.2K EDGAR
2023-04-19 OTLK Grant (A) — $0 EDGAR
2023-01-24 OTLK Sell (S) −267,000 -$296.4K EDGAR
2023-01-19 OTLK Sell (S) −164,155 -$203.7K EDGAR
2022-04-04 OTLK Grant (A) — $0 EDGAR
2021-12-23 Outlook Therapeutics, Inc. (OTLKW) Delisted Grant (A) — $0 EDGAR
2021-12-06 Outlook Therapeutics, Inc. (OTLKW) Delisted Buy (P) +35,200 $47.2K EDGAR
2021-02-25 Outlook Therapeutics, Inc. (OTLKW) Delisted Sell (S) −8,554 -$17.9K EDGAR
2021-02-17 Outlook Therapeutics, Inc. (OTLKW) Delisted Sell (S) −56,973 -$145.3K EDGAR
Showing 1–10 of 11
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.